Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHumeniuk, R.en
dc.contributor.authorOng, J.en
dc.contributor.authorKerr, D.en
dc.contributor.authorWhite, J.en
dc.identifier.citationGeneral Pharmacology, 1995; 26(2):417-424en
dc.description.abstract1. While GABAB antagonists have been examined in vitro, very few have been tested in vivo. A range of GABAB antagonists were tested against baclofen-induced muscle relaxation and hypothermia. 2. The GABAB antagonists exhibited a range of in vivo activity profiles. 3. CGP 35348 showed clear antagonist effects, while BPBA and 4-ABPA appeared to have agonist properties. 4. Phaclofen, 2-hydroxysaclofen, 3-APPA and 9G seemed to have little effect in this system at the doses tested. 5. Differences between in vivo and in vitro activity could be explained by differences in blood-brain barrier permeability, or possible differences in affinities for the sub-classes of GABAB receptors.en
dc.description.statementofresponsibilityRachel E. Humeniuk, Jennifer Ong, David I.B. Kerr and Jason M. Whiteen
dc.rightsCopyright © 2009 Elsevier B.V.en
dc.subjectGABAB receptor; phaclofen; 2-hydroxysaclofen; CEP 35348; BPBA; 4-ABPA; 3-APPA; 9Gen
dc.titleCharacterisation of GABAB ligands in vivoen
dc.typeJournal articleen
pubs.library.collectionAnaesthesia and Intensive Care publicationsen
dc.identifier.orcidOng, J. [0000-0002-0958-460X]en
Appears in Collections:Anaesthesia and Intensive Care publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.